- 1 TITLE: Development and validation of a near-comprehensive RxNorm valueset of opioid
- 2 medications
- AUTHORS: Michael Wasz, MPH^{1,2}, Prabhu RV Shankar, MD, MS⁴, Elizabeth Sprouse, MPH²,
- 5 Lyndsey Kirchner, MPH.⁵, Matthew H. Garber³, James Jones, MPhil³, Kenneth D. Mandl, MD,
- 6 $MPH^{3, 6}$, Andy McMurry Ph.D.^{3, 6}
- 7
- 8 AFFLIATIONS: ¹Emory University Rollins School of Public Health, 1518 Clifton Rd., Atlanta,
- 9 GA 30322
- ²Double Lantern Informatics, 3456 Landen Pine Ct., Atlanta, GA 30305
- ³Computational Health Informatics Program, Boston Children's Hospital, 300 Longwood Ave.,
- 12 Boston, MA 02115
- ⁴Division of Health Informatics, University of California Davis Health, 4610 X Street,
- 14 Sacramento, CA 95817
- ⁵CDC Foundation, 600 Peachtree Street NE, Suite 100, Atlanta GA 30308
- ⁶ Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, United States of
- 17 America
- 18
 19 CORRESPONDING AUTHOR: Michael Wasz, 331-238-2030, mgwasz@gmail.com
- 20
- 21 MAIN TEXT WORD COUNT: 2116
- 22 ABSTRACT WORD COUNT: 184
- 23
- 24 **KEYWORDS:** Analgesics, Opioid; RxNorm; Drug Classification; Electronic Health Records;
- 25 Public Health Informatics

26 ABSTRACT

27

Objective: Develop a near-comprehensive opioid medications valueset for population measures
 of opioid related treatments and outcomes. The opioid valueset should be free, open source, and
 conform to the RxNorm standard federally mandated in every US-certified electronic health
 record.

32

33 Materials and Methods: Cumulus opioid valueset was manually curated by the authors and

34 expanded using computer assisted curation. Opioid classifier rules were developed to select

opioid RxNorm concepts with known opioid receptor interactions, ingredients, keywords, and

- drug product formulations. Twelve publicly available valuesets were used to develop and
 validate the Cumulus opioid valueset. Validation accuracy was measured against a corpus of
- validate the Cumulus opioid valueset. Validation accuracy was measured against a corpus ofopioid medication orders and non-opioid pain relievers.
- 39

40 **Results:** Cumulus opioid valueset recall was >99.9% when measured against opioid prescription

41 RxNorm codes from UC Davis Health and Brigham and Women's Hospital. Cumulus opioid

42 valueset was 100% specific compared to three valuesets of non-opioid pain relievers.

43

44 **Discussion and Conclusion:** To the authors' knowledge, Cumulus opioid valueset is the largest

45 publicly available valueset of opioid medications (8,926 RxNorm concepts). The intended use of

this opioid valueset is for population health measures of opioid medications and related patientoutcomes.

48

49 **INTRODUCTION**

50 Opioid-based analgesia is the most commonly used treatment in postoperative pain management, 51 with more than 95% of surgical patients receiving opioids during hospitalization[1,2]. This 52 accounts to roughly 55 million patients in the United States each year. While many patients 53 treated with opioids recover well, others experience opioid related adverse events[2] or develop 54 opioid use disorder(OUD) [3,4]. To measure the frequency of opioid prescriptions[5,6] and 55 opioid related outcomes[7], a comprehensive vocabulary[8] of opioid medication concepts are 56 needed.

57 Electronic health records (EHR) contain longitudinal patient history[9–11], enabling measurements of patient status before, during, and after medication orders containing opioids, 58 59 [12,13]. By analyzing the frequency of patient care trajectories involving opioid medications, it 60 should be possible to decipher which care trajectories most commonly lead to better or worse 61 outcomes. EHR data is a valuable resource to measure outcomes of opioid use disorder 62 treatments such as naloxone and buprenorphine. At the time of this study, there are at least 30 63 opioid valuesets listed by the US national library of medicine (NLM)[8]. However, it remains 64 unclear which combination of opioid valuesets should be selected to maximize sensitivity and specificity in opioid medication studies. 65

The primary objective of this study is to develop a near comprehensive list of opioid
concepts referencing RxNorm[14]. RxNorm is the federally mandated standard drug vocabulary
in the United States Core Data for Interoperability (USCDI)[11]. RxNorm contains precise drug
type information, including brand names, generic names[15], medication strength, prescribable
drug names[16], and relationships[17,18] to drugs across thirteen common medical vocabularies.
The secondary objective of this study is to enable "push button population health" [9]

measurement of opioid prescriptions and outcomes at national scale by adopting 21st Century
Cures Act [19] mandated health data USCDI standards[11].

This study reports the Cumulus opioid valueset code[20] and data[21], freely available
under the Apache-2.0 open source license. The Cumulus opioid valueset is published on
VSAC[22].

77 METHODS

78 The Cumulus opioid valueset was developed using published sources of opioids[23–30], expert 79 manual curation, and computer assisted curation (Figure 1). Published valuesets were 80 downloaded from the Value Set Authority Center (VSAC)[8]. Authors manually reviewed each 81 opioid entry from an opioid medication valueset[29] using the Unified Medical Language System (UMLS) and Bioportal[31]. Each opioid concept was expanded to a larger valueset of 82 83 opioid concepts having one or more opioid ingredients. Authors then manually curated a list of 84 opioid ingredients, opioid keywords, and opioid classification rules for computer assisted 85 curation. The medication reference terminology [32–34] (MED-RT) was used to automatically 86 select all RxNorm concepts with known opioid receptor interactions[35,36]. Published opioid valuesets[23-30] were processed using opioid ingredients, opioid keywords, and opioid 87 88 classification rules. The valueset aggregation of RxNorm concepts selected for opioid 89 ingredients, opioid keywords, opioid receptor interactions, and opioid classifier rules were used 90 to compile the Cumulus opioid valueset. Three VSAC non-opioid valuesets [37–39] were 91 analyzed to provide examples of medications that do not include opioids. Non-opioid valuesets 92 were used to test if non-opioid concepts were incorrectly included in the Cumulus opioid 93 valueset. Lastly, sources of opioid prescriptions were analyzed to validate real world use of

94 Cumulus opioid valueset in two medical centers.

95 Expert Manual Curation

96 The authors manually reviewed each opioid RxNorm concept from an opioid medications

97 valueset[29] and verified each concept included an opioid ingredient in Bioportal. Each

98 ingredient was then expanded using UMLS to include all RxNorm relationships[40] for all drug

99 product formulations. In addition to ingredient-level curation, opioid keywords were curated to

100 search for additional opioid medications. Common opioid-related terms, including both generic

101 and brand names, were curated and refined iteratively to reduce false positives. The cumulus

102 opioid keyword list was appended with a list of published VSAC valueset of opioid medication

103 keywords[30].

104 Computer Assisted Curation

105 Computer assisted curation was developed to expedite expert manual curation. Two

106 computerized methods were developed: an opioid classifier and an MED-RT medication

107 hierarchy of opioid receptor interactions. The opioid classifier rules were curated to select related

108 opioid medications having similar opioid keywords, brand names, generic names, and multi-

109 ingredient formulations by leveraging relationships such as "ingredient of" and "tradename of."

110 Additional rules were curated to disambiguate drug products with multiple ingredients such as

111 cold medicines containing opioids. In total, the opioid classifier included keywords, ingredient-

112 level relationships, and drug product formulations. The supplementary material contains the

113 complete opioid classifier ruleset for each pair of RxNorm concepts, term types, and relationship

114 attributes.

MED-RT was used to recursively include all RxNorm concepts in a hierarchy of opioid
 receptor interactions. MED-RT concepts were selected matching the keyword "opioid". MED-

117 RT provides a hierarchy of medication classes[32], namely mechanism of action (MoA),

118 established pharmacologic class (EPC), and physiologic effects (PE). Figure 2 illustrates the

119 MED-RT partial hierarchy of Mu (μ) and Kappa (κ) opioid receptor interactions. Delta (δ) and

nociceptin/orphanin FQ (NOP) receptors[41] are not included in the MED-RT hierarchy as there

121 are currently no prescribable opioid medications for delta (δ) and NOP receptors.

122 Accuracy Measurements

123 Sensitivity and specificity were measured for the Cumulus opioid valueset against nine VSAC

124 opioid valuesets[22–29,41] and three VSAC non-opioid valuesets[37–39]. Figure 3 illustrates

accuracy measurements. Sensitivity (recall) was measured as the percentage of VSAC opioid

126 concepts recalled using the Cumulus opioid valueset, using formula true positive (TP) divided by

127 the sum of TP plus false negative (FN) [i.e. TP / (TP + FN)]. Specificity (true negative rate) was

128 measured using formula true negative (TN) divided by the sum of TN plus false positive (FP)

129 [i.e. TN / (TN+FP)]. True positives were defined as opioid concepts in a VSAC opioid valueset.

130 True negatives were defined as opioid concepts in a VSAC non-opioid valueset. False positives

131 were defined as opioid concepts present in both the Cumulus opioid valueset and an VSAC non-

132 opioid valueset. False negatives were defined as opioid concepts present in a VSAC opioid

133 valueset that were not present in the Cumulus opioid valueset. Truth conflicts exist when the

same RxNorm concepts is present in both a VSAC opioid and VSAC non-opioid valueset.

135 VSAC truth conflicts were resolved by authors (MGW, AJM, PRVS) to confirm ground truth

136 labeling.

137 **RESULTS**

138 Cumulus opioid valueset resulted in 8,926 unique opioid RxNorm concepts (Figure 4). To the 139 authors' knowledge, this is the largest publicly available opioid valueset conforming to standards 140 federally mandated in every US-certified electronic health record system. 141 Manual curation of 349 opioid medications[29] using UMLS/BioPortal yielded an 142 expanded list of 2,007 RxNorm concepts. Opioid classifier rules were then used to select an 143 additional set of 3,861 related concepts. MED-RT hierarchy included 1,834 concepts with a 144 known opioid receptor interaction[35], which were then related to an additional 3,766 concepts 145 using the opioid classifier rules. Opioid keywords were used to select 1,864 concepts from 146 published VSAC opioid valuesets, which were then expanded to include 1,520 additional 147 concepts. In total, 8,926 unique RxNorm concepts were selected using manual curation, opioid 148 receptor interactions, opioid keywords, and opioid classifier rules of related RxNorm concepts. 149 Validation 150 Cumulus opioid valueset was tested against multiple opioid and non-opioid valuesets, yielding 151 >99.9% sensitivity and 100% specificity. Cumulus recalled 1,193 of 1,994 unique RxNorm 152 concepts. Of these, Cumulus recalled all 228 concepts for opioid oral tablets and patches from 153 Brigham and Women's Hospital [42]. Cumulus recalled 1007 of 1137 concepts for opioids in the 154 UC Davis Health set of opioid prescriptions. Upon manual review, only 1 of the 130 concepts 155 missing opioid concepts was determined to be a prescribable opioid medication. The single truth 156 conflict was due to the UC Davis Epic EHR medications grouper inadvertently including 157 individual ingredients such as aspirin, ibuprofen, and guaifenesin that are commonly prescribed

158 with codeine.

159	Cumulus opioid valueset specificity was 100% compared to three published VSAC
160	valuesets for non-opioids[37-39]. None of the 3877 non-opioid RXCUIs were present in the
161	Cumulus opioid valueset. Additional validation was performed against 2048 non-opioid concepts
162	in a MED-RT hierarchy containing RxNorm concepts for classes: NSAID, barbiturate, and/or
163	benzodiazepine. Confirmed by manual review, the Cumulus opioid valueset contained zero false
164	positives from any non-opioid valueset[22].
165	VSAC validation rules were applied to the set of 8,926 RxNorm concepts resulting in
166	4,123 active concepts and 4,803 inactive concepts. Both active and inactive concepts are
167	provided to readers to enable historical analysis of opioid prescriptions since the start of the
168	opioid crisis.
169	
170	DISCUSSION
170 171	DISCUSSION To the authors' knowledge, this study presents the largest publicly available valueset of opioid
170 171 172	DISCUSSION To the authors' knowledge, this study presents the largest publicly available valueset of opioid medications using the RxNorm standard. The intended use of the Cumulus opioid valueset is to
170 171 172 173	DISCUSSION To the authors' knowledge, this study presents the largest publicly available valueset of opioid medications using the RxNorm standard. The intended use of the Cumulus opioid valueset is to quickly measure opioid population health statistics across multiple healthcare organizations in
170 171 172 173 174	DISCUSSION To the authors' knowledge, this study presents the largest publicly available valueset of opioid medications using the RxNorm standard. The intended use of the Cumulus opioid valueset is to quickly measure opioid population health statistics across multiple healthcare organizations in parallel[9]. Cumulus is designed for use with US core standards for interoperability(USCDI) [43]
170 171 172 173 174 175	DISCUSSION To the authors' knowledge, this study presents the largest publicly available valueset of opioid medications using the RxNorm standard. The intended use of the Cumulus opioid valueset is to quickly measure opioid population health statistics across multiple healthcare organizations in parallel[9]. Cumulus is designed for use with US core standards for interoperability(USCDI) [43] with over 100 data elements[44] relevant to opioid studies, especially medications[45],
170 171 172 173 174 175 176	DISCUSSION To the authors' knowledge, this study presents the largest publicly available valueset of opioid medications using the RxNorm standard. The intended use of the Cumulus opioid valueset is to quickly measure opioid population health statistics across multiple healthcare organizations in parallel[9]. Cumulus is designed for use with US core standards for interoperability(USCDI) [43] with over 100 data elements[44] relevant to opioid studies, especially medications[45], conditions[46,47], vital signs[48], laboratory results[49], diagnostic reports[50],
170 171 172 173 174 175 176 177	DISCUSSION To the authors' knowledge, this study presents the largest publicly available valueset of opioid medications using the RxNorm standard. The intended use of the Cumulus opioid valueset is to quickly measure opioid population health statistics across multiple healthcare organizations in parallel[9]. Cumulus is designed for use with US core standards for interoperability(USCDI) [43] with over 100 data elements[44] relevant to opioid studies, especially medications[45], conditions[46,47], vital signs[48], laboratory results[49], diagnostic reports[50], observations[51], clinical notes[52], and demographics[53] across a wide range of encounter
170 171 172 173 174 175 176 177 178	DISCUSSION To the authors' knowledge, this study presents the largest publicly available valueset of opioid medications using the RxNorm standard. The intended use of the Cumulus opioid valueset is to quickly measure opioid population health statistics across multiple healthcare organizations in parallel[9]. Cumulus is designed for use with US core standards for interoperability(USCDI) [43] with over 100 data elements[44] relevant to opioid studies, especially medications[45], conditions[46,47], vital signs[48], laboratory results[49], diagnostic reports[50], observations[51], clinical notes[52], and demographics[53] across a wide range of encounter settings[54]. When used with the USCDI data, Cumulus opioid valueset may be used to measure
170 171 172 173 174 175 176 177 178 179	DISCUSSION To the authors' knowledge, this study presents the largest publicly available valueset of opioid medications using the RxNorm standard. The intended use of the Cumulus opioid valueset is to quickly measure opioid population health statistics across multiple healthcare organizations in parallel[9]. Cumulus is designed for use with US core standards for interoperability(USCDI) [43] with over 100 data elements[44] relevant to opioid studies, especially medications[45], conditions[46,47], vital signs[48], laboratory results[49], diagnostic reports[50], observations[51], clinical notes[52], and demographics[53] across a wide range of encounter settings[54]. When used with the USCDI data, Cumulus opioid valueset may be used to measure frequency of opioid prescriptions[55], trajectories of opioid use[56], treatment of opioid use

181	There were several limitations in this study. The Cumulus opioid valueset includes
182	RxNorm opioid medication prescribed by a healthcare professional. Opioids acquired
183	outside[59] of the healthcare system cannot be measured using prescriptions alone[60]. It was
184	beyond the scope of this study to evaluate case definitions of substance use disorders using
185	diagnosis concepts[61] and laboratory results[62]. Despite best efforts, it should be expected that
186	not all cases of opioid use will be counted. The unregulated opioid supply frequently changes
187	ingredient mixtures and chemical structures thus limiting detection using standardized toxicology
188	screens. To estimate the true opioid use prevalence from the apparent opioid use prevalence[63],
189	clinical notes[52] could be reviewed for a small sample of the population to adjust prevalence

190 estimates.

191 LEGENDS OF FIGURES

192 Figure 1 caption: Methods to curate and validate the opioid Cumulus valueset. Published

- 193 sources were human expert curated and expanded using computer assisted curation. The
- 194 Cumulus opioid valueset contains the aggregation from these curated sources. Validation is
- 195 measured against opioid medication orders and non-opioid VSAC valuesets.
- 196 Alt text: Flowchart showing the process for curating and validating the Cumulus opioid valueset.
- 197 Published sources, such as opioid receptor interactions and VSAC valuesets, undergo human
- 198 expert curation and are expanded through computer-assisted curation using tools like MED-RT
- and BioPortal.

200

201 Figure 2 caption: Example RxNorm medications in the MED-RT hierarchy of opioid

202 receptor interactions. Opioid receptors hierarchically link RxNorm ingredients and RxNorm

203 prescribable products. Shaded boxes denote MED-RT hierarchical concepts for the established

204 pharmacologic class of opioid receptor interactions. Arrows denote direction of the hierarchical

205 relationships. Unshaded boxes denote RxNorm medications. Bold denotes RxNorm ingredient

206 concepts. Boxes on the bottom of the hierarchy provide examples of generic names, brand

207 names, dose form, and strength. "Buprenorphine 8 MG / Naloxone 2 MG" illustrates how

208 multiple ingredients can be combined in a single product.

209 Alt text: Hierarchical diagram illustrating the MED-RT hierarchy for opioid receptor

210 interactions. The diagram branches into opioid agonists and antagonists, which further divide

- 211 into full, partial, competitive, and non-competitive subtypes. Examples of RxNorm medications
- 212 include Oxycodone (a full opioid agonist for the Mu receptor) and Narcan (a competitive opioid

antagonist). Additional medications such as Buprenorphine 8 MG / Naloxone 2 MG are shown
as products with combined ingredients.

215

216 Figure 3 caption: Accuracy of ground truth labels against the Cumulus and VSAC

217 valuesets. True positives denote RXCUIs present in both Cumulus opioids and VSAC opioids.

218 False negatives denote RXCUIs present only in VSAC opioids valuesets. False positive RXCUIs

219 denote Cumulus opioids also present in VSAC non-opioids. True negative denotes RXCUIs

220 present only in VSAC non-opioids. Truth conflict denotes RXCUIs present in both VSAC

221 opioids and non-opioids.

Alt text: Venn diagram illustrating the accuracy of Cumulus and VSAC valuesets. True positives

are represented by the overlap between Cumulus opioids and VSAC opioids. False negatives

refer to RXCUIs only present in VSAC opioids, while false positives denote RXCUIs present in

225 Cumulus opioids but also found in VSAC non-opioids. True negatives represent RXCUIs only in

226 VSAC non-opioids. A central section shows truth conflict, where RXCUIs exist in both VSAC

227 opioids and non-opioids.

228

Figure 4 caption: Cumulus opioid valueset curation and validation. Published sources of opioid receptor interactions, opioid keywords, and opioid medications are curated. Human expert curation included UMLS/BioPortal and curation of common opioid keywords. Cumulus assisted curation of opioid receptor interactions and published VSAC opioid valuesets. Cumulus opioid valueset resulted in 8,926 unique RxNorm concepts. Validation was performed against hospital opioid medication orders and valuesets of non-opioid pain-relievers.

- 235 Alt text: Flowchart detailing the process of curating and validating the Cumulus opioid valueset.
- Human expert curation incorporates opioid receptor interactions, keywords, and concepts from
- 237 UMLS/BioPortal. The process expands through computer-assisted curation, adding concepts
- from the MED-RT hierarchy and various VSAC valuesets. The final aggregation yields 8,926
- unique RxNorm concepts, validated against opioid medication orders (99.9% sensitivity) and
- 240 non-opioid valuesets (100% specificity).

241

242 **DECLARATION OF INTERESTS:** Elizabeth Sprouse is the founder of Double Lantern

- 243 Informatics, a for-profit consulting firm, and served as a consultant to the CDC Foundation
- 244 during this project. The author has no significant conflicts of interest that would affect the
- 245 integrity of the research. All other authors declare no conflicts of interest.
- 246 DATA SHARING: Data and code are freely available under the Apache-2.0 license. Code for
- building the Cumulus opioid valueset is available at https://github.com/smart-on-fhir/cumulus-
- 248 <u>library-opioid-valueset</u>. Supplementary data is available at <u>https://github.com/smart-on-</u>
- 249 <u>fhir/cumulus-library-opioid-valueset-supplement</u>.
- 250 **ACKNOWLEDGMENTS:** Authors thank the UC Davis pharmacy and informatics teams with
- 251 special thanks to Eugene Kang and Momeema Ali.
- **FUNDING:** This work was supported by the Office of the National Coordinator for Health
- 253 Information Technology contract numbers 90AX0031/01-00, 90AX0022/01-00, and
- 254 90AX0040/01-00; Centers for Disease Control and Prevention of the United States Department
- 255 of Health and Human Services (HHS) as part of a financial assistance award, Strengthened
- 256 Community Partnerships for More Holistic Approaches to Interoperability totaling \$1,985,178
- 257 (The contents are those of the author(s) and do not necessarily represent the official views of, nor
- an endorsement, by the CDC Foundation, CDC/HHS, or the U.S. Government); The National
- 259 Center for Advancing Translational Sciences/National Institutes of Health Cooperative
- Agreements U01TR002623 and U01TR002997; National Association of Chronic Disease
- 261 Directors/Centers for Disease Control and Prevention Grant No. NU38OT000286; Centers for
- 262 Disease Control and Prevention Grant No. U18DP006500; and Centers for Disease Control and
- 263 Prevention Cooperative Agreement Nos. NU58IP000004 and 1U01TR002997-01A1.

264 **REFERENCES**

265	1	Baker J, Brovman EY, Rao N, et al. Potential Opioid-Related Adverse Drug Events Are Associated
266		With Decreased Revenue in Hip Replacement Surgery in the Older Population. Geriatr Orthop Surg
267		Rehabil. 2020;11:2151459320915328. doi: 10.1177/2151459320915328
268	2	Hospital harm - opioid-related adverse events. https://ecqi.healthit.gov/ecqm/eh/2024/cms0819v2
269		(accessed 5 May 2024)
270	3	Dasgupta N, Beletsky L, Ciccarone D. Opioid Crisis: No Easy Fix to Its Social and Economic
271		Determinants. Am J Public Health. 2018;108:182-6. doi: 10.2105/AJPH.2017.304187
272	4	2019 NSDUH annual national report. https://www.samhsa.gov/data/report/2019-nsduh-annual-
273		national-report (accessed 5 May 2024)
274	5	Seth P, Rudd RA, Noonan RK, et al. Quantifying the Epidemic of Prescription Opioid Overdose
275		Deaths. Am J Public Health. 2018;108:500–2. doi: 10.2105/AJPH.2017.304265
276	6	Fraser M, Plescia M. The Opioid Epidemic's Prevention Problem. Am J Public Health.
277		2019;109:215–7. doi: 10.2105/AJPH.2018.304859
278	7	Ordean A, Tubman-Broeren M. Safety and Efficacy of Buprenorphine-Naloxone in Pregnancy: A
279		Systematic Review of the Literature. Pathophysiology. 2023;30:27-36. doi:
280		10.3390/pathophysiology30010004
281	8	Bodenreider O, Nguyen D, Chiang P, et al. The NLM value set authority center. Stud Health
282		Technol Inform. 2013;192:1224.
283	9	Mandl KD, Gottlieb D, Mandel JC, et al. Push Button Population Health: The SMART/HL7 FHIR
284		Bulk Data Access Application Programming Interface. NPJ Digit Med. 2020;3:151. doi:
285		10.1038/s41746-020-00358-4

- 286 10 McMurry AJ, Gottlieb DI, Miller TA, et al. Cumulus: a federated electronic health record-based
- 287 learning system powered by Fast Healthcare Interoperability Resources and artificial intelligence. J
- 288 Am Med Inform Assoc. 2024;31:1638–47. doi: 10.1093/jamia/ocae130
- 289 11 United States core data for interoperability (USCDI). https://www.healthit.gov/isa/united-states-core-
- data-interoperability-uscdi (accessed 25 October 2023)
- 291 12 Palumbo SA, Adamson KM, Krishnamurthy S, et al. Assessment of Probable Opioid Use Disorder
- Using Electronic Health Record Documentation. *JAMA Netw Open*. 2020;3:e2015909. doi:
- **293** 10.1001/jamanetworkopen.2020.15909
- 294 13 Poulsen MN, Nordberg CM, Troiani V, et al. Identification of opioid use disorder using electronic

health records: Beyond diagnostic codes. *Drug Alcohol Depend*. 2023;251:110950. doi:

- **296** 10.1016/j.drugalcdep.2023.110950
- 297 14 Parrish F, Do N, Bouhaddou O, *et al.* Implementation of RxNorm as a terminology mediation
 298 standard for exchanging pharmacy medication between federal agencies. *AMIA Annu Symp Proc.*299 2006;1057.
- Nelson SJ, Zeng K, Kilbourne J, *et al.* Normalized names for clinical drugs: RxNorm at 6 years. J
 Am Med Inform Assoc. 2011;18:441–8. doi: 10.1136/amiajnl-2011-000116
- Le H, Chen R, Harris S, *et al.* RxNorm for drug name normalization: a case study of prescription
 opioids in the FDA adverse events reporting system. *Front Bioinform.* 2023;3:1328613. doi:
- **304** 10.3389/fbinf.2023.1328613
- 305 17 Bodenreider O. The Unified Medical Language System (UMLS): integrating biomedical
 306 terminology. *Nucleic Acids Res.* 2004;32:D267–70. doi: 10.1093/nar/gkh061
- 307 18 *Metathesaurus*. National Library of Medicine (US) 2021.

- 308 19 Office of the National Coordinator of Health Information Technology. 21st Century Cures Act Final
- **309**Rule. 2020. https://www.healthit.gov/curesrule/resources/information-blocking-faqs (accessed 12)
- **310** February 2023)
- 311 20 Cumulus Opioid Valueset (Code). GitHub Code. https://github.com/smart-on-fhir/cumulus-library-
- 312 opioid-valueset (accessed 10 October 2024)
- 313 21 Cumulus Opioid Valueset (data supplement). https://github.com/smart-on-fhir/cumulus-library-
- 314 opioid-valueset-supplement (accessed 11 October 2024)
- 22 Cumulus Author. Opioids [value set]. VSAC; Published by Cumulus Steward. Updated February
- **316** 2024. Accessed October 28, 2024.
- 317 https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1284.1/definition
- 318 23 CancerLinQ. Opioids. Value Set Authority Center. 2024.
- 319 https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1116.449/expansion (accessed 31 July
- **320** 2024)
- 321 24 IMPAQ International. All Opioids. Value Set Authority Center. 2019.
- 322 https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1196.87/expansion (accessed 31 July 2024)
- 323 25 American College of Emergency Physicians/AMA-PCPI. Opioid Meds. Value Set Authority Center.
- 324 2020. https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1106.68/expansion (accessed 31 July
 325 2024)
- 326 26 Agency for Healthcare Research and Quality Clinical Decision Support Connect Project. Opioid pain
 327 medications. Value Set Authority Center. 2023.
- 328 https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1032.34/expansion (accessed 31 July 2024)
- 329 27 ECRI. All prescribable opioids used for pain control including Inactive Medications. Value Set

- Authority Center. 2015.
- 331 https://vsac.nlm.nih.gov/valueset/1.3.6.1.4.1.6997.4.1.2.234.999.3.2/expansion (accessed 31 July
 332 2024)
- 333 28 Lantana. Schedule II, III and IV Opioid Medications. Value Set Authority Center. 2024.
- 334 https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1046.241/expansion (accessed 31 July
- 335 2024)
- 336 29 Mathematica. Opioid Medications. Value Set Authority Center. 2020.
- 337 https://vsac.nlm.nih.gov/valueset/2.16.840.1.113883.3.3157.1004.26/expansion (accessed 31 July
- 338 2024)
- 339 30 Cliniwiz. Opioid medication key words. Value Set Authority Center.
- 340 https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1200.163/expansion/ (accessed 11 October
 341 2024)
- 342 31 Noy NF, Shah NH, Whetzel PL, et al. BioPortal: ontologies and integrated data resources at the click

343 of a mouse. Nucleic Acids Res. 2009;37:W170–3. doi: 10.1093/nar/gkp440

- 344 32 National Library of Medicine. MED-RT (Medication Reference Terminology). 2018.
- 345 https://www.nlm.nih.gov/research/umls/sourcereleasedocs/current/MED-RT/index.html (accessed 6
 346 May 2024)
- 347 33 Palchuk MB, Klumpenaar M, Jatkar T, *et al.* Enabling Hierarchical View of RxNorm with NDF-RT
 348 Drug Classes. *AMIA Annu Symp Proc.* 2010;2010:577–81.
- 349 34 Pathak J, Murphy SP, Willaert BN, et al. Using RxNorm and NDF-RT to classify medication data
- 350 extracted from electronic health records: experiences from the Rochester Epidemiology Project.
- 351 *AMIA Annu Symp Proc.* 2011;2011:1089–98.

352	35	National Drug File	- Reference	Terminology -	- Opioid Rece	ptor Interactions	[MoA]	- Classes.

- 353 http://purl.bioontology.org/ontology/NDFRT/N0000000200 (accessed 14 August 2024)
- 354 36 Dhaliwal A, Gupta M. *Physiology, Opioid Receptor*. StatPearls Publishing 2023.
- 355 37 CancerLinQ. Non Opioid Analgesics. Value Set Authority Center. 2024.
- 356 https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1260.173/expansion
- 357 38 MD Partners. Non opioid pain medications. Value Set Authority Center. 2020.
- 358 https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1021.73/expansion (accessed 16 October
- 359 2024)
- 360 39 MITRE. Non Opioid from ATC. Value Set Authority Center. 2023.
- 361 https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1032.291/expansion (accessed 16 October
 362 2024)
- 363 40 Appendix 1 RxNorm Relationships (RELA). Published Online First: 1 September 2023.
- 364 41 Toll L, Bruchas MR, Calo' G, et al. Nociceptin/orphanin FQ receptor structure, signaling, ligands,

functions, and interactions with opioid systems. *Pharmacol Rev.* 2016;68:419–57. doi:

- **366** 10.1124/pr.114.009209
- 367 42 Brigham and Women's Hospital. Opioid (Oral Tablets and Patches only). Value Set Authority
- 368 Center. 2019. https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1206.12/expansion (accessed
 369 16 October 2024)
- 370 43 Gov H. USCDI Patient demographics/information. United States Core Data for Interoperability
- 371 (USCDI). https://www.healthit.gov/isa/uscdi-data-class/patient-demographicsinformation (accessed
 372 29 March 2023)
- **373** 44 HL7.FHIR.US.CORE\Profiles and Extensions FHIR v4.0.1.

374	https://hl7.org/fhir/us/core/STU4/profiles-and-extensions.html	(accessed 10 October 2024)
5/4	111105.//111/.012/1111/05/0016/01/04/01011165-0110-0200105.110110	1000000000000000000000000000000000000

- 375 45 HL7.FHIR.US.CORE\US Core MedicationRequest Profile FHIR v4.0.1.
- 376 https://hl7.org/fhir/us/core/StructureDefinition-us-core-medicationrequest.html (accessed 10 October
- 377 2024)
- 378 46 US core condition encounter diagnosis profile US core implementation guide v7.0.0.
- 379 https://hl7.org/fhir/us/core/StructureDefinition-us-core-condition-encounter-diagnosis.html (accessed
 380 10 October 2024)
- 381 47 US Core Condition Problems and Health Concerns Profile US Core Implementation Guide v7.0.0.
- 382 https://hl7.org/fhir/us/core/StructureDefinition-us-core-condition-problems-health-concerns.html
 383 (accessed 10 October 2024)
- 48 US Core Vital Signs Profile US Core Implementation Guide v7.0.0.
- 385 https://hl7.org/fhir/us/core/StructureDefinition-us-core-vital-signs.html (accessed 10 October 2024)
- 386 49 US Core Laboratory Result Observation Profile US Core Implementation Guide v7.0.0.
- 387 https://hl7.org/fhir/us/core/StructureDefinition-us-core-observation-lab.html (accessed 10 October
 388 2024)
- 389 50 US Core DiagnosticReport Profile for Laboratory Results Reporting US Core Implementation
- 390 Guide v7.0.0. https://hl7.org/fhir/us/core/StructureDefinition-us-core-diagnosticreport-lab.html
- **391** (accessed 10 October 2024)
- 392 51 US Core Observation Clinical Result Profile US Core Implementation Guide v7.0.0.
- 393 https://hl7.org/fhir/us/core/StructureDefinition-us-core-observation-clinical-result.html (accessed 10
 394 October 2024)
- 395 52 Clinical Notes US Core Implementation Guide v7.0.0. https://hl7.org/fhir/us/core/clinical-

- 396 notes.html (accessed 10 October 2024)
- 397 53 US Core Patient Profile US Core Implementation Guide v7.0.0.
- 398 https://hl7.org/fhir/us/core/StructureDefinition-us-core-patient.html (accessed 10 October 2024)
- 399 54 US Core Encounter Profile US Core Implementation Guide v7.0.0.
- 400 https://hl7.org/fhir/us/core/StructureDefinition-us-core-encounter.html (accessed 10 October 2024)
- 401 55 Straub L, Huybrechts KF, Hernandez-Diaz S, *et al.* Chronic prescription opioid use in pregnancy in
- the United States. *Pharmacoepidemiol Drug Saf.* 2021;30:504–13. doi: 10.1002/pds.5194
- 403 56 Straub L, Huybrechts KF, Hernández-Díaz S, et al. Trajectories of Prescription Opioid Utilization
- 404During Pregnancy Among Prepregnancy Chronic Users and Risk of Neonatal Opioid Withdrawal

405 Syndrome. Am J Epidemiol. 2022;191:208–19. doi: 10.1093/aje/kwab249

406 57 Straub L, Bateman BT, Hernández-Díaz S, et al. Comparative safety of in utero exposure to

407 buprenorphine combined with naloxone vs buprenorphine alone. *JAMA*. 2024;332:805–16. doi:
408 10.1001/jama.2024.11501

- 409 58 Suarez EA, Huybrechts KF, Straub L, et al. Buprenorphine versus Methadone for Opioid Use
- 410 Disorder in Pregnancy. *N Engl J Med*. 2022;387:2033–44. doi: 10.1056/NEJMoa2203318
- 411 59 Spencer M, Garnett M, Miniño A. Drug overdose deaths in the United States, 2002-2022. National
 412 Center for Health Statistics (U.S.) 2023.
- 413 60 CDC. Understanding the Opioid Overdose Epidemic. Overdose Prevention. 2024.
- 414 https://www.cdc.gov/overdose-prevention/about/understanding-the-opioid-overdose-epidemic.html
 415 (accessed 10 October 2024)
- 416 61 HL7 Patient Care Work Group. Drug Misuse. Value Set Authority Center. 2023.
- 417 https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1222.707/expansion (accessed 10 October

418 2024)

- 419 62 Council of State and Territorial Epidemiologists (CSTE). Opioids, Benzodiazepines, or Barbiturates
- 420 (Tests by Any Method). Value Set Authority Center. 2024.
- 421 https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1146.2293/expansion (accessed 10 October
- 422 2024)
- 423 63 Habibzadeh F, Habibzadeh P, Yadollahie M. The apparent prevalence, the true prevalence. *Biochem*
- 424 *Med* . 2022;32:020101. doi: 10.11613/BM.2022.020101

425

426





Cumulus Opioids



VSAC Opioids

VSAC Non-opioid

Published Sources	Human Expert Curation	Cumputer Assisted Curation			Agregation of Opioid Concepts		Validation
Opioid Receptor Interactions		• 1,834 concepts (MED-RT)	3,766 concepts (Opioid classifier)		8,926 unique Rxnorm concepts (Cumulus Opioid Valuset)		>99.9% Sensitivity
1 VSAC valuset	361 Opioid Keywords		1,864 concepts (Opioid classifier)				opioid medication orders
1 VSAC valuset	2,007 concepts (UMLS / Bioportal)		3,861 concepts (Opioid classifier)				100% Specificity
6 VSAC valusets			1,956 concepts (Opioid classifier)				3 VSAC valuesets: Non-opioid pain relievers